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Abstract
We have recently shown that a new therapeutic modality using the REIC/Dkk-3 gene (Ad-
REIC) is effective against various human cancers, including those of prostate, testis and breast
origins. The aim of the present study was to examine the sensitivity of bladder cancers to Ad-
REIC and to clarify the molecular mechanisms that determine sensitivity/resistance. We found
that 2 human bladder cancer cell lines, T24 and J82, are resistant to Ad-REIC. In T24 and J82
cells, the ER stress response and activation of JNK were observed in a manner similar to that in
the sensitive PC3 cells. Translocation of Bax to mitochondria occurred in PC3 cells but not in T24
and J82 cells. Bcl-2 was remarkably overexpressed in T24 and J82 compared with the expression
levels in sensitive cell lines. Treatment of T24 and J82 cells with a Bcl-2 inhibitor sensitized the
cells to Ad-REIC-induced apoptosis. The results indicate that some human bladder cancers are
resistant to apoptosis induced by overexpression of REIC/Dkk-3, which is at least in part due to
up-regulation of Bcl-2. These results provide a basis for possible use of Bcl-2 as a marker of
sensitive cancers and to try to sensitize resistant cancers to Ad-REIC by down-regulation of Bcl-2.
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We have recently shown that a new therapeutic modality using the REIC/Dkk-3 gene (Ad-REIC) is 
eﬀective against various human cancers,  including those of prostate,  testis and breast origins.  The 
aim of the present study was to examine the sensitivity of bladder cancers to Ad-REIC and to clarify 
the molecular mechanisms that determine sensitivity/resistance.  We found that 2 human bladder can-
cer cell lines,  T24 and J82,  are resistant to Ad-REIC.  In T24 and J82 cells,  the ER stress response and 
activation of JNK were observed in a manner similar to that in the sensitive PC3 cells.  Translocation 
of Bax to mitochondria occurred in PC3 cells but not in T24 and J82 cells.  Bcl-2 was remarkably 
overexpressed in T24 and J82 compared with the expression levels in sensitive cell lines.  Treatment of 
T24 and J82 cells with a Bcl-2 inhibitor sensitized the cells to Ad-REIC-induced apoptosis.  The results 
indicate that some human bladder cancers are resistant to apoptosis induced by overexpression of 
REIC/Dkk-3,  which is at least in part due to up-regulation of Bcl-2.  These results provide a basis for 
possible use of Bcl-2 as a marker of sensitive cancers and to try to sensitize resistant cancers to 
Ad-REIC by down-regulation of Bcl-2.
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nvasive bladder cancer is a potentially fatal 
disease.  Approximately 30ｵ of bladder cancer 
cases are invasive at initial diagnosis,  and 10ﾝ15ｵ of 
superﬁcial bladder cancer cases progress to invasive 
cancer during the disease course [1].  When the can-
cer is conﬁned to the bladder,  radical cystectomy 
combined with pelvic lymphadenectomy results in a 
5-year survival rate of approximately 75ｵ with no 
appreciable tumor progression.  It is diﬃcult,  how-
ever,  to detect lymphatic micrometastasis in remote 
tissues prior to surgical resection,  and lymphatic 
micrometastasis leads to poor prognosis with a pro-
gression-free 5-year survival rate of only 25ﾝ30ｵ 
due to recurrence of cancer [2].  Postoperative recur-
rence of bladder cancer is often found in remote lymph 
nodes and/or organs rather than in neighboring tissues 
of the bladder,  indicating that remote micrometastasis 
is critical for eventual recurrence.  Neoadjuvant che-
motherapy using cisplatin,  methotrexate,  vinblastine 
and doxorubicine has been conducted,  but the diﬀer-
ence in 5-year survival after surgical resection alone 
and that after surgical resection combined with neoad-
juvant chemotherapy remains statistically elusive (p＝
0.06) [3].  In addition,  the side eﬀects of systemic 
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application of anti-cancer drugs remain a major chal-
lenge despite the development of new drugs and 
improvements in regimens.  Patients with invasive 
bladder cancer often suﬀer from irreversible renal 
insuﬃciency due to urinary retention or obstruction of 
the ureter.  Renal insuﬃciency is another complicating 
factor preventing well-controlled application of chemo-
therapeutic agents.
　 Gene therapy is a promising new approach that may 
circumvent the problems described above.  A number 
of diﬀerent genes,  including p53,  HSV-derived thymi-
dine kinase and TRAIL,  have been intensively 
exploited as potential therapeutic modalities [4ﾝ6].  
We have recently reported that REIC/Dkk-3,  a newly 
identiﬁed tumor suppressor gene [7,  8],  might be 
useful for gene therapy.  Expression of REIC/Dkk-3 
was found to be reduced in many diﬀerent types of 
human cancers [8ﾝ13],  mainly due to hypermethyl-
ation of the promoter region [14].  When overex-
pressed using an adenovirus vector (Ad-REIC),  
REIC/Dkk-3 induced apoptosis in prostate cancer 
cells but not in normal prostate epithelial cells,  
despite similar expression levels in both cells [9].  A 
single injection of Ad-REIC had a dramatic anti-tumor 
eﬀect on a xenotransplanted human prostate cancer.  In 
addition,  Ad-REIC was shown not only to induce 
apoptosis but also to inhibit local invasion and metas-
tasis in an orthotopic prostate cancer model in mice 
[10].  Ad-REIC is also eﬀective for human testicular 
cancer [11].
　 The original idea of using a tumor suppressor gene 
as a tool for gene therapy is to correct the deterio-
rated function of the corresponding tumor suppressor 
genes in cancer cells.  Although REIC/Dkk-3 is a 
secretory protein and is assumed to exert its physio-
logical function from the cell surface,  the induction of 
apoptosis in cancer cells by Ad-REIC has been shown 
to be primarilly due to ER stress loaded by overpro-
duction of REIC/Dkk-3 in the cells [9,  11].  
Activation of c-Jun N-terminal kinase (JNK) triggered 
by ER stress is a critical event for apoptosis induced 
by Ad-REIC.
　 Although Ad-REIC has been shown to be eﬀective 
to many diﬀerent types of human cancers,  we have 
also noted that not all human cancers are sensitive to 
Ad-REIC.  It is important,  therefore,  to determine 
factors that are responsible for the sensitivity/resis-
tance of cancer cells to Ad-REIC in order to select 
cases in which Ad-REIC can be used and to develop 
strategies for overcoming resistance.  In the present 
study,  we identiﬁed 2 human bladder cancer cell lines 
that are resistant to Ad-REIC and we analyzed the 
intracellular signal transduction pathway triggered by 
Ad-REIC in the resistant cell lines compared to that 
in sensitive control cell lines.  We found that overex-
pression of Bcl-2 is a factor conferring resistance of 
cells to Ad-REIC-induced apoptosis.
Materials and Methods
　 Reagents, cells, and culture. Human transi-
tional cell carcinoma (TCC) cell lines derived from the 
bladder,  including T24 and J82,  the prostate cancer 
cell line PC3,  the osteosarcoma cell line Saos2,  and 
the germ cell tumor NCCIT were purchased from 
ATCC (Rockville,  MD,  USA).  A normal human 
embryonic ﬁbroblast line,  OUMS-24,  was established 
and provided by Dr.  M.  Namba [15].  McCoyʼs 5A 
medium, MEM, Hamʼs F-12 K medium, and Dulbeccoʼs 
modiﬁed MEM were used for T24,  J82,  PC3,  and 
OUMS-24,  respectively,  with a supplement of 10ｵ 
FBS and antibiotics.  Saos2 and NCCIT were main-
tained in RPMI1640 supplemented with 10ｵ fetal 
bovine serum.  Subfractionation of cells was per-
formed using a Mitochondrial Fractionation kit 
(Active Motif,  Carlsbad,  CA,  USA).  A Bcl-2 inhibi-
tor,  YC-137,  was purchased from CALBIOCHEM 
(San Diego,  CA,  USA).
　 RT-PCR. A full-length cDNA of REIC/Dkk-3 
was integrated into the cosmid vector pAxCAwt and 
transferred into an adenovirus vector (Ad-REIC) by 
the COS-TPC method (TAKARA BIO,  Shiga,  
Japan).  An adenovirus vector carrying the LacZ gene 
(Ad-LacZ) was used as a control.  The virus vectors 
were ampliﬁed in HEK 293 cells and puriﬁed using an 
Adeno-X Virus Purification kit (Clontech 
Laboratories,  Mountain View,  CA,  USA).
　 Adenovirus vector carrying REIC/Dkk-3.
To determine the infection eﬃciency,  cells were 
infected with Ad-LacZ.  Twenty-four hours after 
infection, the cells were washed with PBS, ﬁxed at 4℃ 
for 3 min in 0. 2ｵ glutaraldehyde and 1ｵ formalde-
hyde,  rinsed twice with PBS,  and then stained with 
5-bromo-4-chloro-3-indolyl ｹ-D-galactoside (X-Gal 
[BRL,  Gaithersburg]) at 37℃ for 12h.
　 Cytotoxicity/apoptosis assay. Cell viability 
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was assessed using a LIVE/DEADⓇ Cell viability 
Fluorometric (green/red) Assay kit (Molecular 
Probes).  Dead cells were identiﬁed as those stained 
red.  Alternatively,  cells with shrunken or fragmented 
nuclei,  as demonstrated by staining with Hoechst 
33342,  were regarded as apoptotic cells.
　Western blot analysis. Forty-eight h after 
adenoviral infection,  cells were washed in PBS,  ﬁxed 
at 4℃ in 10ｵ trichloroacetic acid,  harvested,  and 
lysed in an 8M urea solution.  Extracted protein 
samples were separated by gel electrophoresis and 
transferred onto a polyvinylidene diﬂuoride (PVDF) 
membranes.  After blocking in 10ｵ skim milk,  the 
membranes were incubated overnight with primary 
antibodies at 4℃.  The membranes were washed with 
PBS,  incubated with secondary antibodies at room 
temperature for 1h,  and rinsed with PBS.  Signals 
were visualized using ECL PlusTM (Amersham 
Biosciences).  The antibodies used were as follows: 
rabbit anti-human REIC/Dkk-3 antibody raised in our 
laboratory; Apoptosis Sampler I kit (BD Biosciences) 
for Bcl-2,  Bcl-xL,  Nip,  and XIAP; rabbit anti-human 
Bax antibody (Upstate Cell Signaling Solutions);  
mouse anti-human tubulin antibody (Sigma); mouse 
anti-horse cytochrome c antibody (Upstate 
Biotechnology,  Lake Placid,  NY,  USA); mouse anti-
mouse mitochondrial Hsp70 (Abcam,  Cambridge,  
UK); rabbit anti-human Hsp27 antibody (Santa 
Cruz); rabbit anti-human Hsp40 antibody (Stressgen 
Bioreagents,  British Columbia,  Canada); rabbit anti-
human c-Jun antibody,  rabbit anti-human phospho-c-
Jun (Ser63) antibody,  rabbit anti-human JNK (c-Jun 
N-terminal kinase) antibody,  rabbit anti-human phos-
pho-JNK (Thr183/Tyr185) antibody,  and rabbit anti-
human Hsp70/73 antibody (Cell Signaling Technology,  
Beverly,  MA,  USA).
　 Electromobility shift assay of a target ele-
ment of ATF-6. For an electromobility shift 
assay,  a cis-acting endoplasmic reticulum (ER) stress 
response element (ERSE: 5ʼﾝCCAATCAGAAAGT 
GGCACGﾝ3ʼ) in the human CHOP promoter was used 
as a DNA probe [16].  The double-stranded probe 
(0.5ｻg) was labeled with 32P in the presence of 10ｻ
Ci of [ｺ-32P]-ATP (Institute of Isotopes of 
Hungarian Academy of Sciences: HAS,  Budapest,  
Hungary) and T4 polynucleotide kinase (New England 
Biolabs: NEB,  Tozer Road Beverly,  MA,  USA).  
The electromobility shift assay was carried out by 
adding 2ｻg of crude nuclear extracts of cells to each 
reaction mixture (20ｻl) containing 2. 5ng of the 
labeled probe,  60mM KCl,  5mM MgCl2,  0.1mM 
EDTA,  1ｻg poly (dI-dC),  1mM dithiothreitol 
(DTT),  5ｵ glycerol,  and 20mM Hepes/pH 7.9.  For 
a super shift experiment,  2ｻg of a rabbit anti-human 
ATF6 antibody (Abcam,  Cambridge,  UK) or of a 
control rabbit IgG (Vector Laboratories,  Burlingame,  
CA,  USA) was added to the reaction mixture.  DNA/
protein complexes were then separated by electropho-
resis in a 5ｵ polyacrilamide gel under non-denaturing 
conditions.
Results
　 Resistance of human bladder cancer cell lines 
to Ad-REIC-induced apoptosis. We ﬁrst exam-
ined the endogenous protein levels of REIC/Dkk-3 in 
human TCC cell lines.  All of the six TCC cell lines 
examined showed remarkably low or undetectable 
levels of REIC/Dkk-3,  as demonstrated by RT-PCR 
and Western blot analysis (data not shown).  Among the 
cell lines,  we chose T24 and J82 for further analyses 
since these cell lines were shown to be relatively 
remote in their gene expression proﬁle [17].
　The infection eﬃciency of Ad-REIC to T24 and J82 
cells was similar to that to PC3 as assessed using 
Ad-LacZ (Fig.  1A).  Furthermore,  the expression 
levels of REIC/Dkk-3 protein in T24 or J82 cells 
infected with Ad-REIC were similar to those in 
OUMS-24 and PC3 cells (Fig.  1B).  Apoptotic cell 
death,  however,  was induced by Ad-REIC in PC3 
cells but not in either T24 cells or J82 cells (Figs.  
1C and 1D).  This result was unexpected since cancer 
cells lacking endogenous expression of REIC/Dkk-3 
were mostly sensitive to Ad-REIC.  We therefore 
analyzed the intracellular signal transduction pathway 
triggered by Ad-REIC.
　 Signal transduction triggered by Ad-REIC in 
human bladder cancer cell lines. In our previ-
ous studies [9,  11,  18],  the triggering event leading 
to apoptosis by Ad-REIC was shown to be ER stress.  
Activation of JNK was shown to be the essential 
downstream step,  followed by translocation of Bax 
protein from the cytoplasm to mitochondria and even-
tual release of cytochrome C into the cytoplasm.  ER 
stress by overexpression of REIC/Dkk-3 was more 
directly conﬁrmed by an electromobility shift assay,  
395Resistance of Bladder Cancers to Ad-REICDecember 2008
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Fig.  1　 Transitional cell carcinoma cell lines were resistant to apoptosis induced by Ad-REIC.            A,  Infection eﬃciency of Ad-LacZ (20 
MOI) in human transitional carcinoma cell lines,  T24 and J82.  PC3,  a human prostate cancer cell line,  was used as a positive control.  
Successfully infected cells were identiﬁed by intracellular β-galactosidase activity (in blue) 24h after infection.  Scale bars,  50µm; B,  
Overexpression of REIC/Dkk-3 using an adenovirus vector (Ad-REIC).  Ad-LacZ was used as a control.  OUMS-24 cells,  normal human 
ﬁbroblasts,  were used as a control; C,  the viability of cells examined 48h after infection with Ad-REIC at 20 MOI.  Cell nuclei were stained 
blue by Hoechst 33342.  Dead cells were stained red by an ethidium bromide dimer (Eth-D).  OUMS-24 and PC3 cells were used as 
negative and positive controls,  respectively.  Scale bars,  500µm; D,  Quantitation of apoptotic cells shown in A.  Vertical bars indicate the 
standard deviation.  ＊p＜0.05.
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which showed that ATF6,  a well-known sensor mole-
cule for ER stress [19],  was activated to bind to an 
ER stress responsive element in the CHOP promoter 
(Fig.  2A).  Expression of CHOP was induced in PC3,  
T24 and J82 cells but not in OUMS-24 cells (Fig.  
2B).  Activation of JNK demonstrated by phosphory-
lation of JNK itself and of the substrate c-Jun was also 
observed in the 3 cancer cell lines but not in 
OUMS-24 cells.  Translocation of Bax to and release 
of cytochrome C from mitochondria were observed in 
the sensitive PC3 cells but not in the T24 and J82 
cells that were resistant to Ad-REIC-induced apopto-
sis (Fig.  2C).  These results indicate that there was 
interference with a signal transduction step between 
activation of JNK and translocation of Bax in the 
resistant T24 and J82 cells.
　 Overexpression of Bcl-2 as a cause of resis-
tance to Ad-REIC-induced apoptosis. We next 
screened expression of apoptosis-related proteins and 
heat shock proteins (Fig.  3).  NCCIT and Saos2 were 
included for the analysis as cell lines sensitive to and 
resistant to Ad-REIC-induced apoptosis.  Except for 
Hsp 40 and Nip,  the expression levels of the proteins 
varied among cell lines.  The expression levels of Bcl-2 
were most notable,  since the protein was overex-
pressed in the 3 resistant cancer cell lines in common 
compared with the expression levels of Bcl-2 in the 2 
sensitive cancer cell lines.  Overexpression of anti-
apoptotic Bcl-xL and down-regulation of proapoptotic 
XIAP in T24 and J82 cells were also noted.  
　 If overexpression of Bcl-2 is responsible for the 
resistance of cells to Ad-REIC-induced apoptosis,  
inhibition of Bcl-2 should restore the sensitivity.  As 
shown in Fig.  4,  apoptosis was induced in T24 and 
J82 cells by infection with Ad-REIC when the cells 
were treated in advance with the Bcl-2 inhibitor 
YC137.
Discussion
　 REIC/Dkk-3 was ﬁrst identiﬁed as a gene whose 
expression is reduced in immortalized cell lines com-
pared to that in their normal counterparts and was 
subsequently shown to be a candidate tumor suppres-
sor gene [8].  Expression of the REIC/Dkk-3 gene 
was later shown to be reduced in many human cancer 
cells and tissues,  including prostate cancer,  renal 
clear cell carcinoma,  non-small cell lung caner,  and 
testicular germ cell tumor [9,  11ﾝ13].  Forced 
expression of REIC/Dkk-3 using an adenovirus vector 
was found to induce apoptotic cell death in REIC/
Dkk-3-deﬁcient cancer cells but not in REIC/Dkk-3-
proﬁcient normal cells [9,  11,  18].  This result was 
conﬁrmed in transplanted cancer cells in vivo.
　 Our previous studies have indicated that Ad-REIC 
induces apoptotic cell death through ER stress and not 
by physiological functions as a secreted protein.  
Mda-7/IL-24 is one of the most potent and promising 
gene therapeutic agents against various human cancers 
[20].  Recently,  mda-7 was shown to exert its tumor-
speciﬁc cell-killing eﬀect at least partly through ER 
stress [21].  Application of puriﬁed REIC/Dkk-3 
protein from the culture medium did not aﬀect the 
survival of any of the cancer cell lines examined (our 
unpublished results).  Overexpression of non-func-
tional partial peptides of REIC/Dkk-3 also induced 
apoptosis in PC3 cells (manuscript submitted).  ATF6,  
a sensor protein of ER stress [19],  was activated and 
CHOP,  an indicator gene of ER stress [22],  was 
induced in the cancer cell lines examined (Figs.  2A 
and 2B).  CHOP,  one of the target genes of activated 
ATF6 [16],  was not induced to any appreciable lev-
els in OUMS-24 cells,  although activation of ATF was 
observed in an electromobility shift assay.  This result 
may have been due to the presence of a factor(s) sup-
pressing the expression of CHOP in OUMS-24 cells 
or due to the involvement of some other pathways in 
the induction of CHOP [23].
　 Activation of JNK has been shown to be essential 
for Ad-REIC-induced apoptosis [9].  Treatment with 
an inhibitor of JNK and with an inhibitor of the down-
stream eﬀector Bax abrogated the apoptotic cell death 
in PC3 cells.  In T24 and J82 cells,  activation of JNK 
but not translocation of Bax from the cytoplasm to 
mitochondria was observed upon infection with 
Ad-REIC (Figs.  2B and 2C),  indicating that a step 
from JNK to Bax is a branching point of cell survival 
or cell death.  Bcl-2 family proteins are characterized 
by containing at least one of the four Bcl-2 homology 
domains (BH1-BH4).  Some of the member proteins,  
including Bcl-2 and Bcl-xL,  function as typical anti-
apoptotic proteins,  while other members such as Bax 
and Bak promote apoptosis.  It is thought that Bcl-2 
dimerizes with Bax through its BH1 and BH2 domains 
and thereby inhibits the function of Bax to destabilize 
the outer mitochondrial membrane [24].  The ratio of 
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Fig.  2　 Signal transduction pathway triggered by Ad-REIC and leading to apoptosis.          A,  Electromobility shift assay of an ER stress 
response element (ERSE: 5ʼﾝCCAATCAGAAAGTGGCACGﾝ3ʼ) in the human CHOP promoter,  a target of ATF6 activated by ER stress.  
Nuclear extracts were prepared from cells infected with Ad-REIC at 20 MOI at 42h.  For a super shift experiment,  a rabbit anti-human ATF6 
antibody was added to the reaction mixtures.  Open arrowhead,  shifted probes; black arrowhead,  super-shifted probes; B,  Western blot 
analysis for proteins involved in the signal transduction.  Cells were treated under the same conditions as those described in A.  P-JNK and 
P-cJun are phosphorylated JNK and cJun.  Tubulin was used as a control for loaded amounts of protein.  LacZ and REIC indicate infection 
with Ad-LacZ and with Ad-REIC,  respectively; C,  Western blot analysis for proteins involved in the signal transduction performed using a 
mixture of designated antibodies.  Mt (mitochondrial) HSP70 and tubulin were used as markers for mitochondrial and cytoplasmic fractions,  
respectively.
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Bcl-2 to Bax dictates susceptibility to an apoptotic 
stimulus [24].  It is conceivable,  therefore,  that 
overexpression of Bcl-2 consistently observed in the 
cancer cell lines inert to Ad-REIC-induced apoptosis 
is the mechanistic cause for the resistance.  YC137 
interferes with Bcl-2 function by blocking protein-
protein interaction via the SH3 domain.  Treatment of 
T24 and J82 cells with YC137 restored the sensitivity 
of those cells to Ad-REIC (Fig.  4).
　 The functional signiﬁcance of Bcl-2 has been exten-
sively investigated both in basic and clinical studies on 
urothelial carcinomas,  and clinical oncologists have 
shown interest in Bcl-2 not only as a biomarker but 
also as a target of molecular therapy.  Overexpression 
of Bcl-2 has been shown to correlate to varying 
degrees with poor prognosis and early recurrence of 
bladder cancer [25ﾝ27] and with resistance to chemo-
therapy and gene therapy [28,  29].  Down-regulation 
of Bcl-2 using antisense oligonucleotides at least par-
tially sensitizes bladder cancers to cisplatin and 
radiotherapy [30,  31].  The results of the present 
study indicate that overexpression of Bcl-2 confers 
upon some bladder cancer cell lines at least partial 
resistance to gene therapy using Ad-REIC,  which has 
been shown to be a very potent tumor-speciﬁc modality 











































Fig.  4　 Sensitization of T24 and J82 cells to Ad-REIC-induced apoptotic cell death by a Bcl-2 inhibitor. The cells were treated under                    
conditions similar to those described in the legend to Fig.  1.  YC137 (0.5mM) was added 36h after infection.  At 42h and 54h after 
infection,  apoptotic cells with shrunken or fragmented nuclei were determined after staining with Hoechst33342.  Vertical bars indicate the 





























Fig.  3　 Western blot analysis for apoptosis-related proteins and       
heat shock proteins in various cell lines.  Tubulin was used as a 
control for the loaded amounts of proteins.
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against many other cancers.  It has been reported that 
not all human bladder cancer cells overexpress Bcl-2 
[25ﾝ27].  We therefore should examine the possibility 
of diagnosing sensitive bladder cancer cases using 
expression of Bcl-2 as a marker and try to sensitize 
bladder cancer cells to Ad-REIC by down-regulation 
of Bcl-2 using siRNA,  miRNA and low-molecular-
weight substances as well as oligonucleotides.  The 
results of the present study provide a basis for such 
lines of research,  which will eventually lead to the 
development of more potent and patient-friendly thera-
peutic measures.
Acknowledgments.　The authors declare that they have no conﬂicts 
of interest.  This study was ﬁnancially supported in part by grants from 
the Japan Society for the Promotion of Science (15390491; Y.  Nasu),  
from the Ministry of Education,  Culture,  Sports,  Science,  and 
Technology of Japan (20015031; N. Huh),  and from Special Coordination 
Funds for Promoting Science and Technology (H.  Kumon).
References
 1.  Malkowicz SB,  van Poppel H,  Mickisch G,  Pansadoro V,  Thuroﬀ J,  
Soloway MS,  Chang S,  Benson M and Fukui I: Muscle-invasive 
urothelial carcinoma of the bladder.  Urology (2007) 69: 3ﾝ16.
 2.  Stein JP and Skinner DG: Radical cystectomy for invasive bladder 
cancer: long-term results of a standard procedure.  World J Urol 
(2006) 24: 296ﾝ304.
 3.  Grossman HB,  Natale RB,  Tangen CM,  Speights VO,  Vogelzang 
NJ,  Trump DL,  deVere White RW,  Sarosdy MF,  Wood DP Jr,  
Raghavan D and Crawford ED: Neoadjuvant chemotherapy plus 
cystectomy compared with cystectomy alone for locally advanced 
bladder cancer.  N Engl J Med (2003) 349: 859ﾝ866.
 4.  Pagliaro LC: Gene therapy for bladder cancer.  World J Urol (2000) 
18: 148ﾝ151.
 5.  Sutton MA,  Freund CT,  Berkman SA,  Dang TD,  Kattan MW,  
Wheeler TM,  Rowley DR and Lerner SP: In vivo adenovirus-medi-
ated suicide gene therapy of orthotopic bladder cancer.  Mol Ther 
(2000) 2: 211ﾝ217.
 6.  Mizutani Y,  Nakao M,  Ogawa O,  Yoshida O,  Bonavida B and 
Miki T: Enhanced sensitivity of bladder cancer cells to tumor 
necrosis factor related apoptosis inducing ligand mediated apopto-
sis by cisplatin and carboplatin.  J Urol (2001) 165: 263ﾝ270.
 7.  Tsuji T,  Miyazaki M,  Sakaguchi M,  Inoue Y and Namba M: A 
REIC gene shows down-regulation in human immortalized cells 
and human tumor-derived cell lines.  Biochem Biophys Res 
Commun (2000) 268: 20ﾝ24.
 8.  Tsuji T,  Nozaki I,  Miyazaki M,  Sakaguchi M,  Pu H,  Hamazaki Y,  
Iijima O and Namba M: Antiproliferative activity of REIC/Dkk-3 
and its signiﬁcant down-regulation in non-small-cell lung carcino-
mas.  Biochem Biophys Res Commun (2001) 289: 257ﾝ263.
 9.  Abarzua F,  Sakaguchi M,  Takaishi M,  Nasu Y,  Kurose K,  Ebara S,  
Miyazaki M,  Namba M,  Kumon H and Huh NH: Adenovirus-
mediated overexpression of REIC/Dkk-3 selectively induces apop-
tosis in human prostate cancer cells through activation of c-Jun-
NH2-kinase.  Cancer Res (2005) 65: 9617ﾝ9622.
10.  Edamura K,  Nasu Y,  Takaishi M,  Kobayashi T,  Abarzua F,  
Sakaguchi M,  Kashiwakura Y,  Ebara S,  Saika T,  Watanabe M,  
Huh NH and Kumon H: Adenovirus-mediated REIC/Dkk-3 gene 
transfer inhibits tumor growth and metastasis in an orthotopic pros-
tate cancer model.  Cancer Gene Ther (2007) 14: 765ﾝ772.
11.  Tanimoto R,  Abarzua F,  Sakaguchi M,  Takaishi M,  Nasu Y,  
Kumon H and Huh NH: REIC/Dkk-3 as a potential gene therapeu-
tic agent against human testicular cancer.  Int J Mol Med (2007) 
19: 363ﾝ368.
12.  Nozaki I,  Tsuji T,  Iijima O,  Ohmura Y,  Andou A,  Miyazaki M,  
Shimizu N and Namba M: Reduced expression of REIC/Dkk-3 
gene in non-small cell lung cancer.  Int J Oncol (2001) 19: 117ﾝ
121.
13.  Kurose K,  Sakaguchi M,  Nasu Y,  Ebara S,  Kaku H,  Kariyama R,  
Arao Y,  Miyazaki M,  Tsushima T,  Namba M,  Kumon H and Huh 
NH: Decreased expression of REIC/Dkk-3 in human renal clear 
cell carcinoma.  J Urol (2004) 171: 1314ﾝ1318.
14.  Kobayashi K,  Ouchida M,  Tsuji T,  Hanafusa H,  Miyazaki M,  
Namba M,  Shimizu N and Shimizu K: Reduced expression of the 
REIC/Dkk-3 gene by promoter-hypermethylation in human tumor 
cells.  Gene (2002) 282: 151ﾝ158.
15.  Bai L,  Mihara K,  Kondo Y,  Honma M and Namba M:
Immortalization of normal human ﬁbroblasts by treatment with 
4-nitroquinoline 1-oxide.  Int J Cancer (1993) 53: 451ﾝ456.
16.  Yoshida H,  Okada T,  Haze K,  Yanagi H,  Yura T,  Negishi M and 
Mori K: ATF6 activated by proteolysis binds in the presence of 
NF-Y (CBF) directly to the cis-acting element responsible for the 
mammalian unfolded protein response.  Mol Cell Biol (2000) 
20: 6755ﾝ6767.
17.  Sanchez-Carbayo M,  Socci ND,  Charytonowicz E,  Lu M,  
Prystowsky M,  Childs G and Cordon-Cardo C: Molecular proﬁling 
of bladder cancer using cDNA microarrays: deﬁning histogenesis 
and biological phenotypes.  Cancer Res (2002) 62: 6973ﾝ6980.
18.  Abarzua F,  Sakaguchi M,  Tanimoto R,  Sonegawa H,  Li DW,  
Edamura K,  Kobayashi T,  Watanabe M,  Kashiwakura Y,  Kaku H,  
Saika T,  Nakamura K,  Nasu Y,  Kumon H and Huh NH: Heat 
shock proteins play a crucial role in tumor-speciﬁc apoptosis by 
REIC/Dkk-3.  Int J Mol Med (2007) 20: 37ﾝ43.
19.  Haze K,  Yoshida H,  Yanagi H,  Yura T and Mori K: Mammalian 
transcription factor ATF6 is synthesized as a transmembrane pro-
tein and activated by proteolysis in response to endoplasmic reticu-
lum stress.  Mol Biol Cell (1999) 10: 3787ﾝ3799.
20.  Fisher PB: Is mda-7/IL-24 a “magic bullet” for cancer? Cancer 
Res (2005) 65: 10128ﾝ10138.
21.  Sieger KA,  Mhashilkar AM,  Stewart A,  Sutton RB,  Strube RW,  
Chen SY,  Pataer A,  Swisher SG,  Grimm EA,  Ramesh R and 
Chada S: The tumor suppressor activity of MDA-7/IL-24 is medi-
ated by intracellular protein expression in NSCLC cells.  Mol Ther 
(2004) 9: 355ﾝ367.
22.  Wang XZ,  Lawson B,  Brewer JW,  Zinszner H,  Sanjay A,  Mi LJ,  
Boorstein R,  Kreibich G,  Hendershot LM and Ron D: Signals from 
the stressed endoplasmic reticulum induce C/EBP-homologous 
protein (CHOP/GADD153).  Mol Cell Biol (1996) 16: 4273ﾝ4280.
23.  Ma Y,  Brewer JW,  Diehl JA and Hendershot LM: Two distinct 
stress signaling pathways converge upon the CHOP promoter dur-
ing the mammalian unfolded protein response.  J Mol Biol (2002) 
318: 1351ﾝ1365.
24.  Oltvai ZN,  Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes 
in vivo with a conserved homolog,  Bax,  that accelerates pro-
grammed cell death.  Cell (1993) 74: 609ﾝ619.
25.  Ye D,  Li H,  Qian S,  Sun Y,  Zheng J and Ma Y: bcl-2/bax 
expression and p53 gene status in human bladder cancer: relation-
400 Acta Med.  Okayama　Vol. 62, No. 6   Kobayashi et al.
8
Acta Medica Okayama, Vol. 62 [2008], Iss. 6, Art. 6
http://escholarship.lib.okayama-u.ac.jp/amo/vol62/iss6/6
ship to early recurrence with intravesical chemotherapy after resec-
tion.  J Urol (1998) 160: 2025-2028; discussion 9.
26.  Cooke PW,  James ND,  Ganesan R,  Burton A,  Young LS and 
Wallace DM: Bcl-2 expression identiﬁes patients with advanced 
bladder cancer treated by radiotherapy who beneﬁt from neoadju-
vant chemotherapy.  BJU Int (2000) 85: 829ﾝ835.
27.  Karam JA,  Lotan Y,  Karakiewicz PI,  Ashfaq R,  Sagalowsky AI,  
Roehrborn CG and Shariat SF: Use of combined apoptosis bio-
markers for prediction of bladder cancer recurrence and mortality 
after radical cystectomy.  Lancet Oncol (2007) 8: 128ﾝ136.
28.  Miyake H,  Hanada N,  Nakamura H,  Kagawa S,  Fujiwara T,  Hara 
I,  Eto H,  Gohji K,  Arakawa S,  Kamidono S and Saya H:
Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis 
induced by cisplatin and adenoviral-mediated p53 gene transfer.  
Oncogene (1998) 16: 933ﾝ943.
29.  Cho HJ,  Kim JK,  Kim KD,  Yoon HK,  Cho MY,  Park YP,  Jeon 
JH,  Lee ES,  Byun SS,  Lim HM,  Song EY,  Lim JS,  Yoon DY,  
Lee HG and Choe YK: Upregulation of Bcl-2 is associated with 
cisplatin-resistance via inhibition of Bax translocation in human 
bladder cancer cells.  Cancer Lett (2006) 237: 56ﾝ66.
30.  Duggan BJ,  Maxwell P,  Kelly JD,  Canning P,  Anderson NH,  
Keane PF,  Johnston SR and Williamson KE: The eﬀect of anti-
sense Bcl-2 oligonucleotides on Bcl-2 protein expression and 
apoptosis in human bladder transitional cell carcinoma.  J Urol 
(2001) 166: 1098ﾝ1105.
31.  Bolenz C,  Becker A,  Trojan L,  Schaaf A,  Cao Y,  Weiss C,  Alken 
P and Michel MS: Optimizing chemotherapy for transitional cell 
carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxy-
nucleotides.  Urol Oncol (2007) 25: 476ﾝ482.
401Resistance of Bladder Cancers to Ad-REICDecember 2008
9
Kobayashi et al.: Mechanistic Analysis of Resistance to REIC/Dkk-3-induced Apoptosi
Produced by The Berkeley Electronic Press, 2008
10
Acta Medica Okayama, Vol. 62 [2008], Iss. 6, Art. 6
http://escholarship.lib.okayama-u.ac.jp/amo/vol62/iss6/6
